Instructions for CME/NCPD: Complete the pre-test, listen to the
audio and view the slides, complete the post test, complete the
evaluation form and hit submit. You will be asked to enter your name
and email address on the pre-test, evaluation and post-test. If you
close your internet browser without completing the post test, you
will have ONE more opportunity to complete. A score of 70% must be
achieved on the post test to receive continuing education credits.
If you do not pass the post test after two attempts, you will not be
eligible to try again. Once you complete the evaluation form and
score 70% or higher on your post test, you will automatically be
given your certificate.
To print or save your certificate, you will need to click on the
“download” button and either print or save.
This activity is intended for healthcare professionals practicing in
managed care environments.
This activity is supported by
educational grants from
AbbVie, Bristol Myers Squibb, and Jazz Pharmaceuticals
Acute myeloid leukemia (AML) is a cancer of the myeloid line of
blood cells, characterized by the rapid growth of abnormal white
blood cells that build up in the bone marrow and interfere with the
production of normal blood cells. AML is the most common acute
leukemia affecting adults, and its incidence increases with age.
Although AML is a relatively rare disease, accounting for roughly
1.2% of cancer deaths in the United States, its incidence is
expected to increase as the population ages. The American Cancer
Society estimates that there were approximately 19,940 new cases of
AML and 11,180 deaths from AML in the United States in 2020. The
five-year survival rate has not improved in older patients despite
of 40 years of research. Fortunately for patients with AML, many new
treatments have recently been approved for use. These options, which
are among the first new treatments in AML since 1990, have begun to
drastically change the treatment paradigm. With that change comes a
knowledge gap among physician medical directors, oncologists,
practicing physicians and nurses. For this reason, it is critical
that these HCPs are educated and updated on these emerging options
and strategies for their implementation into the treatment paradigm,
which will ultimately improve patient outcomes in the AML patient
AML has several subtypes and treatment and prognosis vary among
subtypes. After AML has been diagnosed, tests are done to find out
the subtype. This is especially important, as several new treatments
focus on AML disease with certain mutations or on patients who are
unable to receive chemotherapy regimens. Following older treatment
paradigms, AML has been cured in 35-40% of people under 60 years
old, but only in 5-15% of people over 60 years old. Fortunately for
people with AML, that treatment paradigm is set to change
drastically, as novel targeted agents have shown improved efficacy
and safety outcomes in clinical trial research. It is imperative
that physician medical directors, oncologists, practicing
physicians, nurse case managers and other healthcare professionals
are brought up to date regarding these new therapy options.
Upon completion of this
activity, participants will be able to:
Examine the clinical and economic
burden of AML in terms of relative survival, mortality, drug
utilization, adverse event management, and hospitalizations
Compare and contrast the efficacy,
safety and mechanisms of action of novel therapeutics in AML,
including newer targeted, cytotoxic, and antibody-based
strategies, in a range of patient populations
Analyze the evolving role of FLT3,
IDH1/2, and BCL-2 inhibitors in the management of AML patients
who are unable to undergo intensive chemotherapy
Examine the role of DNA
hypomethylating agents as maintenance therapy for patients with
AML in first remission
Discuss newer cytotoxic therapy
options and distinguish differences in new chemotherapy
induction regimens compared to standard formulations
Employ interventions such as
clinical pathways and site of care initiatives for optimal cost
management and improved outcomes in AML
||Harry P. Erba, MD, PhD
Professor of Medicine
Director, Leukemia Program
Duke University Medical Center
serves as a consultant for AbbVie, Agios, Astellas, BMS/Celgene,
Genentech, Incyte, Jazz Pharmaceuticals, Novartis,
Glycomimetics, Kura Oncology, and Trillium. He serves on
the speaker's bureau for AbbVie, Agios, BMS/Celgene,
Incyte, Jazz Pharmaceuticals, and Novartis. His
presentation has been peer reviewed for any bias.
MD has no financial relationships with ineligible
companies to disclose.
Jeremy Williams has no financial relationships with
ineligible companies to disclose.
Jacqueline Cole, RN, MS, CMCN has no financial
relationships with ineligible companies to disclose.
NAMCP and/or the presenter
has copyright or has received permissions for use of
materials provided in this activity.
Accreditation & Designation
This activity has been planned and implemented in accordance with
the accreditation requirements and policies of the Accreditation
Council for Continuing Medical Education (ACCME) through the joint
providership of the National Association of Managed Care Physicians
(NAMCP) and American Association of Managed Care Nurses (AAMCN). The
National Association of Managed Care Physicians is accredited by the
ACCME to provide continuing medical education for physicians.
NAMCP designates this enduring material for a maximum of 1 AMA
PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their
participation in the activity.
The American Association of Managed Care Nurses is accredited as a
provider of nursing continuing professional development by the
American Nurses Credentialing Center's Commission on Accreditation.
Nurses who complete this activity and achieve a passing score will
receive 1 hour in nursing continuing professional development.
This activity has been approved by the American Board of Managed
Care Nursing for 1.0 contact hours toward CMCN recertification
This activity is supported by educational grants from
AbbVie, Bristol Myers Squibb, and Jazz Pharmaceuticals
NAMCP and/or this website does not
provide medical advice, diagnosis or treatment. NAMCP does not
endorse or imply endorsement of the content on any linked website.
This website is to be used as an informational resource. With any
health related concern, consult with your physician or healthcare
Click Here To Continue